Skip to content
Menu

AnaptysBio, Inc. ANAB

Full chart Compare
Set alert

Price alert · ANAB

All alert types
46.63 USD -0.77 (-1.62%)

Regular-session close

46.63 0.00 0.00%

After hours · Nov 20, 4:38 PM ET

46.05 Day range 47.66
25.11 52-week range 69.81
YTD
+44.28%
1 year
+85.70%

5D +0.62 (+1.35%)

4648MonTueWedThuFri46.65
Market cap
1.39B
Revenue (ttm)
60.04M
Profit margin
417.63%
EPS (ttm)
6.52
Shares out
29.73M
P/E ratio
7.15
Forward P/E
8.65
YTD return
+44.28%
1-year return
+85.70%
50-day average
49.02
Volume
432.45K
Avg volume
495.13K
Open
46.63
Previous close
47.40
Day's range
46.05 – 47.66
52-week range
25.11 – 69.81
Beta
0.37
Analysts
Strong Buy
Price target
87.25 (+87.1%)
Earnings date
Mar 2, 2027

Key statistics

200-day average
51.47
Enterprise value
1.52B
Price / sales
23.08
Price / book
67.06
Revenue growth
-60.30%
Total cash
152.99M
Total debt
262.39M
Short % of float
37.03%

Fundamental scorecard

9 of 25 checks passed on ANAB’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 2 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ANAB Revenue — quarterly 30.27M
ANAB Net income — quarterly 3.88M
ANAB EPS — quarterly 0.13

Earnings

ANAB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 20260.54———
Nov 12, 2026Sep 30, 2026-1.840.11+1.95+105.98%
Sep 21, 2026Jun 30, 20265.115.110.000.00%
May 12, 2026Mar 31, 2026-0.32-1.84-1.52-475.00%
Mar 3, 2026Dec 31, 20250.891.58+0.69+77.53%
Nov 4, 2025Sep 30, 2025-1.060.52+1.58+149.06%

Upgrades / downgrades

ANAB analyst upgrades and downgrades
DateFirmActionFromTo
Sep 30, 2026JP MorganmainOverweightOverweight
Sep 24, 2026HC Wainwright & Co.reitBuyBuy
Sep 23, 2026Leerink PartnersmainOutperformOutperform
Aug 25, 2026TD CowenmainBuyBuy
Aug 24, 2026HC Wainwright & Co.reitBuyBuy
May 13, 2026UBSmainBuyBuy

About AnaptysBio, Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ANAB — it syncs with the Stock Master app.

Insider holders

ANAB insider holders
InsiderRelationLatest transactionDateShares held
ECOR1 CAPITAL, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityPurchaseNov 17, 20260
FAGA DANIEL RChief Executive OfficerSaleMar 26, 2026495,965
JAIN RITADirectorConversion of Exercise of derivative securityJun 12, 202511,864
LIZZUL PAUL F.OfficerSaleJan 7, 202642,088
LOUMEAU ERIC JOSEPHOfficerSaleFeb 10, 202612,835
MARQUET MAGDADirectorSaleJan 14, 20269,930

Institution ownership

ANAB institution ownership
Holder% heldSharesValueReported
EcoR1 Capital, LLC26.51%7,880,094367.29MSep 29, 2026
Blackrock Inc.6.36%1,891,51288.16MSep 29, 2026
Tang Capital Management, LLC4.96%1,474,26268.72MSep 29, 2026
State Street Corporation3.85%1,145,90153.41MSep 29, 2026
Vanguard Capital Management LLC3.06%909,94642.41MSep 29, 2026
Goldman Sachs Group Inc2.86%850,34339.63MSep 29, 2026

Fund ownership

ANAB fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.18%648,14630.21MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.15%640,36329.85MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.76%522,20924.34MSep 29, 2026
TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund0.89%263,84012.30MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.80%237,03211.05MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.73%215,69710.05MSep 29, 2026